Skip to content
drillr.ai

REGN

Regeneron Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$672.15-0.67%

Price as of Jul 20, 2026

REGN news

Regeneron Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Securities Lawsuit Alert: Regeneron Pharmaceuticals, Inc. (REGN) – Contact Levi & Korsinsky Before September 14, 2026

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 20, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/ny6z) or contact Joseph E

    ACCESSWIRE ·

  2. Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

    Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress PR Newswire MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights([1]) * Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-yea

    PR Newswire ·

  3. Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky to Join Class Action Before September 14, 2026

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 20, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nxt4) or contact Jos

    ACCESSWIRE ·

  4. Recover Investment Losses: Class Action Initiated Against Regeneron Pharmaceuticals, Inc. (REGN)

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 20, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nxgy) or contact Jos

    ACCESSWIRE ·

  5. REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

    NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025 and May 15, 2026, inclusive. What To Do Next: Investors are encouraged to act promptly and submit a form at Regeneron Pharmaceuticals, Inc. Shareholder Class Action Lawsuit (

    Globe Newswire ·

  6. REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action – Contact Levi & Korsinsky

    NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Check if you might be eligible to recover your investment losses (https://www.globenewswire.com/Tracker?data=5RBXrA0AGi26EH9UgVQNipRiQV868rPT_ltQ1JfkhXnfWsu6SOeCkp2XGBI2Z2D_Fy7JkvWDTNGUuCq-R7NOaFtNFSMeNeOMYWHe9odDCL78jpneEe2dBLOt

    Globe Newswire ·

  7. Levi & Korsinsky Urges Regeneron Pharmaceuticals, Inc. (REGN) Shareholders to Act Before Lead Plaintiff Deadline September 14, 2026

    NEW YORK, NY / ACCESS Newswire / July 20, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nx0k) or contact Joseph E. Levi, Esq. via email at jlevi@le

    ACCESSWIRE ·

  8. Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. (REGN) Investors – Lead Plaintiff Deadline on September 14, 2026

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 19, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nwrc) or contact Joseph E

    ACCESSWIRE ·

  9. Class Action Alert: Levi & Korsinsky Reminds Regeneron (REGN) Investors of September 14, 2026 Deadline

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 19, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nwnm) or contact Joseph E

    ACCESSWIRE ·

  10. Securities Fraud Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) – Levi & Korsinsky Reminds Investors of September 14, 2026

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 18, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nwhc) or contact Joseph E

    ACCESSWIRE ·

  11. Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

    Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN The DJS Law Group (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdjslawllp.com%2F&esheet=54572619&newsitemid=20260718371295&lan=en-US&anchor=The+DJS+Law+Group&index=1&md5=e464051de0b1568e3e9ed64fb301554e) reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN (https://cts.busines

    Business Wire ·

  12. REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm The Schall Law Firm (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54572783&newsitemid=20260717679733&lan=en-US&anchor=The+Schall+Law+Firm&index=1&md5=b379e667c15d9c34fa5eb9d32d3b3966) , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” o

    Business Wire ·

  13. Shareholders of Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights Before September 14, 2026 - Contact Levi & Korsinsky

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 17, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nvrl) or contact Jos

    ACCESSWIRE ·

  14. REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker (https://www.globenewswire.com/Tracker?data=AchOqEG-QnHdqL_h5dvg3Z0D09hBXMHdP2sGt4WznUWk-CJG4IuJ0vG3pAljc7HkZgnhFwZ5BAuIkiXnB04K9fF9UAnkhXGOQKu4C2kCual9UztCsblJGJBcMr0crQ_d) Encourages Investors Who Suffered Losses In Regeneron (REGN) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Regeneron common stock between August 1, 2025, and May 15, 2026 and would like to discuss your legal rights, contac

    Globe Newswire ·

  15. Regeneron Pharmaceuticals, Inc. (REGN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 14, 2026

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 17, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) securities. If you suffered a loss on your Regeneron investment and would like to explore a potential recovery under the federal securities laws, Learn about Regeneron Class Action (https://pr.report/nuyw) or contact Jos

    ACCESSWIRE ·

  16. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Regeneron Pharmaceuticals, Inc. Common Stock and Sets a Lead Plaintiff Deadline of September 14, 2026

    NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, inclusive. You are hereby notified that the class action lawsuit Allen Cheatham v. Regeneron Pharmaceuticals, Inc., et al. (Case No. 7:26-cv-06026) has been commenced in the United States D

    Globe Newswire ·

  17. Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

    TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s web

    Globe Newswire ·

  18. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 14, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [

    ACCESSWIRE ·

  19. REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

    REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm The Schall Law Firm (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54551691&newsitemid=20260610917236&lan=en-US&anchor=The+Schall+Law+Firm&index=221&md5=3dec927af0acd807238d6b2573f1c062) , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (

    Business Wire ·

  20. Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN. (https://bgandg.com/REGN/?utm_source=accesswire&utm_medium=pressrelease

    ACCESSWIRE ·